Infinity Pharmaceuticals Analyst Ratings
Infinity Pharmaceuticals Analyst Ratings
B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5
B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating
No Data